Literature DB >> 14630995

Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients.

Elena Sotillo-Piñeiro1, Luis Sierrasesúmaga, Ana Patiñno-García.   

Abstract

The presence of telomerase activity has been analyzed in almost all tumor types and tumor-derived cell lines. However, there are very few studies that focus on the presence of telomerase activity in bone tumors, and most of them report analysis on very few samples or bone-derived cell lines. The objective of this study was to analyze the telomere length and telomerase activity in primary tumors and metastatic lesions from pediatric osteosarcoma and Ewing's sarcoma patients. The presence of telomerase activity was analyzed by the telomeric repeat amplification protocol assay, and the telomere length was measured by Southern blot. Results were related to survival and clinical outcome. Telomerase activity was detected in 85% of the bone tumor metastases (100% Ewing's sarcomas and 75% osteosarcomas) but only in 12% of the primary tumors (11.1% osteosarcomas and 12.5% Ewing's sarcomas). Bone tumor tissues with telomerase activity had mean telomere lengths 3 kb shorter than those with no detectable telomerase activity (p = 0.041). The presence of telomerase activity was associated with survival (p = 0.009), and longer event-free survival periods were found in patients who lacked telomerase activity compared with those who had detectable telomerase activity levels in their tumor tissues (p = 0.037). The presence of longer telomeres in primary pediatric bone tumors than in metastases could be indicative of alternative mechanisms of lengthening of telomeres for their telomere maintenance rather than telomerase activity. Nevertheless, the activation of telomerase seems to be a crucial step in the malignant progression and acquisition of invasive capability of bone tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14630995     DOI: 10.1203/01.PDR.0000102455.36737.3C

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  14 in total

1.  Different expression of alternative lengthening of telomere (ALT)-associated proteins/mRNAs in osteosarcoma cell lines.

Authors:  Yi Zhang; Lin Cai; Ren-Xiong Wei; Hao Hu; Wei Jin; Xiao-Bin Zhu
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

2.  Biomarkers in Osteosarcoma.

Authors:  Colin Kong; Marc F Hansen
Journal:  Expert Opin Med Diagn       Date:  2009-01-01

3.  Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.

Authors:  Guidong Li; Hiroyuki Kawashima; Akira Ogose; Takashi Ariizumi; Yongjun Xu; Tetsuo Hotta; Yasuo Urata; Toshiyoshi Fujiwara; Naoto Endo
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-31       Impact factor: 4.553

Review 4.  Means to the ends: The role of telomeres and telomere processing machinery in metastasis.

Authors:  Nathaniel J Robinson; William P Schiemann
Journal:  Biochim Biophys Acta       Date:  2016-10-18

5.  Potent growth-inhibitory effect of TRAIL therapy mediated by double-regulated oncolytic adenovirus on osteosarcoma.

Authors:  Chunbao Li; Li Chunbao; Qianpeng Cheng; Cheng Qianpeng; Jia Liu; Liu Jia; Bin Wang; Wang Bin; Dongfeng Chen; Chen Dongfeng; Yujie Liu; Liu Yujie
Journal:  Mol Cell Biochem       Date:  2012-02-22       Impact factor: 3.396

6.  Clinical significance of telomere length and associated proteins in oral cancer.

Authors:  Rachana N Sainger; Shaila D Telang; Shilin N Shukla; Prabhudas S Patel
Journal:  Biomark Insights       Date:  2007-02-14

7.  Targeted therapies for bone sarcomas.

Authors:  Dominique Heymann; Françoise Rédini
Journal:  Bonekey Rep       Date:  2013-07-17

8.  Bone sarcomas: from biology to targeted therapies.

Authors:  Nathalie Gaspar; Angela Di Giannatale; Birgit Geoerger; Françoise Redini; Nadège Corradini; Natacha Enz-Werle; Franck Tirode; Perrine Marec-Berard; Jean-Claude Gentet; Valérie Laurence; Sophie Piperno-Neumann; Odile Oberlin; Laurence Brugieres
Journal:  Sarcoma       Date:  2012-11-27

Review 9.  The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications.

Authors:  Marta Recagni; Joanna Bidzinska; Nadia Zaffaroni; Marco Folini
Journal:  Cancers (Basel)       Date:  2020-04-11       Impact factor: 6.639

10.  Glucose restriction combined with chemotherapy decreases telomere length and cancer antigen-125 secretion in ovarian carcinoma.

Authors:  Stephanie Antoun; David Atallah; Roula Tahtouh; Mona Diab Assaf; Malak Moubarak; Eliane Nasser Ayoub; Georges Chahine; George Hilal
Journal:  Oncol Lett       Date:  2019-12-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.